Literature DB >> 26548591

An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis.

Li-Wen Liu1, Tomoyuki Nishikawa1, Yasufumi Kaneda1.   

Abstract

Inactivated Sendai virus (hemagglutinating virus of Japan; HVJ) envelope (HVJ-E) induces anticancer immunity and cancer cell-selective apoptosis through the recognition of viral RNA genome fragments by retinoic acid-inducible gene-I (RIG-I). Here, we discovered that the "copy-back" type of defective-interfering (DI) particles that exist in the Cantell strain of HVJ induced the human PC3 prostate cancer cell death more effectively than the Sendai/52 strain or Cantell strain, which contain fewer DI particles. DI particle genomic RNA (~550 bases) activated proapoptotic genes such as Noxa and/or TNF-related apoptosis-inducing ligand (TRAIL) in human prostate cancer cells to induce cancer cell-selective apoptosis. DI particle-derived RNA was synthesized by in vitro transcription (in vitro transcribed (IVT)-B2). IVT-B2 RNA, which has a double-stranded region in its secondary structure, promoted a stronger anticancer effect than IVT-HN RNA, which does not have a double-stranded region in its secondary structure. The intratumoral transfection of IVT-B2 significantly reduced the volume of a human prostate tumor and induced tumor cell apoptosis in the xenograft mouse model. Moreover, the involvement of natural killer (NK) cells in IVT-B2-RNA-induced anticancer effects was also suggested. These findings provide a novel nucleic acid medicine for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26548591      PMCID: PMC4754554          DOI: 10.1038/mt.2015.201

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  35 in total

1.  Differential recognition of viral RNA by RIG-I.

Authors:  Alina Baum; Adolfo García-Sastre
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

2.  TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles.

Authors:  Taeko Matsushima-Miyagi; Koji Hatano; Motonari Nomura; Liu Li-Wen; Tomoyuki Nishikawa; Kotaro Saga; Takashi Shimbo; Yasufumi Kaneda
Journal:  Clin Cancer Res       Date:  2012-09-26       Impact factor: 12.531

3.  Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing.

Authors:  Alina Baum; Ravi Sachidanandam; Adolfo García-Sastre
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

Review 4.  Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool.

Authors:  Yasufumi Kaneda
Journal:  Expert Opin Drug Deliv       Date:  2010-09       Impact factor: 6.648

5.  The structural basis of 5' triphosphate double-stranded RNA recognition by RIG-I C-terminal domain.

Authors:  Cheng Lu; Hengyu Xu; C T Ranjith-Kumar; Monica T Brooks; Tim Y Hou; Fuqu Hu; Andrew B Herr; Roland K Strong; C Cheng Kao; Pingwei Li
Journal:  Structure       Date:  2010-07-15       Impact factor: 5.006

6.  Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle.

Authors:  Yoshifumi Kawaguchi; Yasuhide Miyamoto; Takehiro Inoue; Yasufumi Kaneda
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

7.  Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon.

Authors:  Masahiko Tanaka; Takashi Shimbo; Yasushi Kikuchi; Masahide Matsuda; Yasufumi Kaneda
Journal:  Int J Cancer       Date:  2010-04-15       Impact factor: 7.396

8.  Sendai virus C protein plays a role in restricting PKR activation by limiting the generation of intracellular double-stranded RNA.

Authors:  Kenji Takeuchi; Takayuki Komatsu; Yoshinori Kitagawa; Kiyonao Sada; Bin Gotoh
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

9.  A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant.

Authors:  L Martínez-Gil; P H Goff; R Hai; A García-Sastre; M L Shaw; P Palese
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

10.  Structural insights into RNA recognition by RIG-I.

Authors:  Dahai Luo; Steve C Ding; Adriana Vela; Andrew Kohlway; Brett D Lindenbach; Anna Marie Pyle
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

View more
  7 in total

Review 1.  A Virus Is a Community: Diversity within Negative-Sense RNA Virus Populations.

Authors:  Lavinia J González Aparicio; Carolina B López; Sébastien A Felt
Journal:  Microbiol Mol Biol Rev       Date:  2022-06-23       Impact factor: 13.044

2.  Enterovirus A71 Oncolysis of Malignant Gliomas.

Authors:  Xiaowei Zhang; Hanzhong Wang; Yuhan Sun; Mi Qi; Wei Li; Zhiping Zhang; Xian-En Zhang; Zongqiang Cui
Journal:  Mol Ther       Date:  2020-04-14       Impact factor: 11.454

Review 3.  RIG-I: a multifunctional protein beyond a pattern recognition receptor.

Authors:  Xiao-Xiao Xu; Han Wan; Li Nie; Tong Shao; Li-Xin Xiang; Jian-Zhong Shao
Journal:  Protein Cell       Date:  2017-06-08       Impact factor: 14.870

Review 4.  Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.

Authors:  David L Elion; Rebecca S Cook
Journal:  Oncotarget       Date:  2018-06-22

Review 5.  The Antiviral and Antitumor Effects of Defective Interfering Particles/Genomes and Their Mechanisms.

Authors:  Yicheng Yang; Taibiao Lyu; Runing Zhou; Xiaoen He; Kaiyan Ye; Qian Xie; Li Zhu; Tingting Chen; Chu Shen; Qinghua Wu; Bao Zhang; Wei Zhao
Journal:  Front Microbiol       Date:  2019-08-09       Impact factor: 5.640

6.  Cancer immunotherapy using the Fusion gene of Sendai virus.

Authors:  Jiayu A Tai; Chin Yang Chang; Tomoyuki Nishikawa; Yasufumi Kaneda
Journal:  Cancer Gene Ther       Date:  2019-08-06       Impact factor: 5.987

7.  Replication defective viral genomes exploit a cellular pro-survival mechanism to establish paramyxovirus persistence.

Authors:  Jie Xu; Yan Sun; Yize Li; Gordon Ruthel; Susan R Weiss; Arjun Raj; Daniel Beiting; Carolina B López
Journal:  Nat Commun       Date:  2017-10-06       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.